This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.
In 2020, Ghana switched from using ROTARIX® to ROTAVAC® in its national immunization program. PATH worked with Ghana Health Service and the University of Ghana to analyze the economic implications of this switch. These four fact sheets explore the key results of these analyses, collectively providing a case study on Ghana’s rotavirus vaccine product switch.
(Manuscript pending submission to a peer-reviewed journal.)
Publication date: May 2022